This week we look at a new migraine medicine, a rescheduling of cannabidiol for epilepsy and a successful trial for neuromyelitis optica spectrum disorder.
GW Pharmaceuticals announced the approval of EPIDIOLEX® (cannabidiol) oral solution as the first plant-derived cannabinoid prescription medication.
Hannah Cock provides insight into the current data, controversies and pipelines for the use of cannabis-derived therapeutics in epilepsy.
Pharmaceutical policy announcements, promising drug trial data and more: check out our round-up of the biggest news from the neuroscience and neurology industry this week
New findings suggest a link between epilepsy and variation in the thickness and volume of certain brain regions.
Preliminary trial indicates signs of CTE in young epilepsy patients – but how strong is the evidence?
A study into children with epileptic encephalopathy has uncovered associated genes, which could lead to the development of novel treatment strategies.
Neural activity resembling epileptic events has been found in multiple GCaMP6-expressing transgenic mouse lines, potentially complicating interpretation of neural activity in the lines.
Polymorphisms in ABCB1 and EPHX1 genes influence drug effectiveness in refractory epilepsy: a retrospective study
This communication examines the association between the number of seizures in refractory epileptic patients and potential interactions between their antiepileptic medications and single nucleotide polymorphisms.
This Review looks at the literature surrounding recent neurophysiological techniques and novel surgical tools in pediatric epilepsy.